Oral Oncology Reports最新文献

{"title":"Bone absorption and deformity in mandible as initial symptom and manifestation of neurofibromatosis type 1: A case report and literature review","authors":"Lini Deng,&nbsp;Yi Wang,&nbsp;Xianwang Xiang,&nbsp;Chuanjun Chen","doi":"10.1016/j.oor.2023.100132","DOIUrl":"10.1016/j.oor.2023.100132","url":null,"abstract":"<div><div>Neurofibromatosis type 1 (NF-1) is an autosomal dominant inherited genodermatosis disease and tumor susceptibility syndrome with a prevalence of 1/6000–1/3000 reported in most epidemiological studies and 1/3333–1/2558 in live births. NF1 is caused by pathogenic variants in the NF1 gene on autosome 17q11.2, and characterized by abnormal pigmentation of the skin，such as café-au-lait macules (CALM), freckles in the armpits or groin area. Additionally, NF1 patients frequently have optic path-way gliomas (OPG), Lisch nodules, plexiform neurofibromas, skeletal abnormalities (dysplasia of long bones, scoliosis), learning and behavioral disabilities, autism spectrum symptoms, seizures, sleep disorders, vasculopathies (moyamoya syndrome, renal artery stenosis) and non-neurological cancers (breast cancer, pheochromocytoma). Among tumors involving the nervous system, peripheral nerve sheath tumors (cutaneous and plexiform neurofibromas) predominate, and 8–13 % of plexiform neurofibroma patients developing malignant peripheral nerve sheath tumors. We report a case of NF1 with initial symptom and manifestation in low jaw in this paper and review the relevant literature to introduce the epidemiological characteristics, pathogenesis, clinical manifestations, latest diagnostic basis and follow-up of NF1.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100132"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139872627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression pattern of lncRNA H19 in oral squamous cell carcinoma tissues in comparison to normal tissues. A systematic review","authors":"Ramya Sekar ,&nbsp;Selvaraj Jayaraman ,&nbsp;Saranya Varadarajan ,&nbsp;Thodur Madapusi Balaji ,&nbsp;Vishnupriya Veeraraghavan ,&nbsp;Prabhu Shankar Dayasankar ,&nbsp;Dharshini Devi J","doi":"10.1016/j.oor.2025.100720","DOIUrl":"10.1016/j.oor.2025.100720","url":null,"abstract":"<div><h3>Background</h3><div>With a high mortality rate, oral squamous cell carcinoma (OSCC), accounts for more than 90 % of all mouth cancers and is a major global health concern. The necessity for trustworthy biomarkers is highlighted by the fact that early diagnosis and prognosis are still difficult despite advancements. A key factor in cancer biology, the long non-coding RNA H19 was first discovered for its function in embryogenesis. H19, reactivated in cancers, interacts with microRNAs and signaling pathways such as p53 and PI3K/AKT to affect tumor growth, invasion, and metastasis. Nevertheless, its expression patterns in OSCC in contrast to healthy tissues remain unclear. The evidence currently available about H19's expression in OSCC is assessed in this review.</div></div><div><h3>Methods</h3><div>The keywords H19 or lncRNA H19 or long non-coding RNA H19″ AND “oral cancer or oral squamous cell carcinoma or tongue squamous cell carcinoma or OSCC” were used to search databases such as PubMed, Scopus, and Clinical Key on 9th December 2024. In addition, the authors manually scanned the reference lists of the included studies or relevant reviews identified through the search to ensure literature saturation. Following the exclusion of duplicates and irrelevant articles, full-text screening of the remaining articles was done to select the articles based on inclusion and exclusion criteria. The Risk of Bias in the included studies was evaluated using the Newcastle Ottawa scale (NOS).</div></div><div><h3>Results</h3><div>Of 95 articles obtained (55 from PubMed, 19 from Scopus, 20 from Clinical Key, and 1 from cross-reference), 56 duplicates or irrelevant articles were eliminated. Of the 39 articles, only eight were selected after the full-text screening of nine articles based on eligibility criteria. All the articles reported a low risk of bias and all the studies reported a change in the expression pattern of H19 in oral squamous cell carcinoma compared to the control.</div></div><div><h3>Conclusion</h3><div>Despite some variability in the direction of changes in H19 expression, most studies have shown its dysregulation in OSCC tissues, highlighting its significance in the pathogenesis of OSCC.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100720"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143265558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oropharyngeal mucoepidermoid carcinoma: A systematic review of the literature","authors":"Gabriela A. Calcano ,&nbsp;Adam E. Brown ,&nbsp;Kelly L. Staricha ,&nbsp;Rumeal D. Whaley ,&nbsp;Patrick W. McGarrah ,&nbsp;Mauricio E. Gamez ,&nbsp;Daniel L. Price ,&nbsp;Kendall K. Tasche ,&nbsp;Linda X. Yin ,&nbsp;Eric J. Moore ,&nbsp;Kathryn M. Van Abel","doi":"10.1016/j.oor.2024.100695","DOIUrl":"10.1016/j.oor.2024.100695","url":null,"abstract":"<div><h3>Importance</h3><div>There is a lack of evidence-based recommendations for patient work up, counseling, and management for mucoepidermoid carcinoma of the oropharynx (OPMEC).</div></div><div><h3>Objective</h3><div>We aim to summarize the published data on OPMEC and report the demographics, clinical presentation, histology, treatment strategies, and oncologic outcomes in OPMEC.</div></div><div><h3>Methods</h3><div>A comprehensive medical librarian-led systematic search was conducted of multiple comprehensive databases according to PRISMA guidelines. We searched for articles published through July 7, 2023, and updated the search on February 27, 2024. This was supplemented by a manual search on PubMed and of the bibliographies of included manuscripts. Review articles, national database studies, abstracts and studies not reporting on primary OPMEC were excluded. Inclusion criteria included human studies, population &gt;18 years, peer-reviewed articles, English language, and reports including data of interest for patients with primary OPMEC. The review was conducted by two independent reviewers (GAC and AEB) and conflicts were resolved by the senior author (KMV). Findings were summarized and descriptive statistics were reported.</div></div><div><h3>Results</h3><div>Twenty-six publications – 2 case series and 24 case reports - describing 80 patients were included. Patients were predominantly female (30/54, 55.6 %) with a median age of 53 years (range: 19–88). OPMEC was most common in the base of tongue (41/54, 75.9 %) and most patients had an oropharyngeal mass noted on examination. Tumors were frequently T1/2 when reported (27/37, 72.9 %). Histological grade was most commonly intermediate grade (31/80, 38.7 %). There were 34 reports of nodal involvement. 21 cases reported both nodal involvement and grade, 5 of which were low grade, 10 intermediate grade, and 6 high grade primary tumors. The most commonly reported treatment modality was surgery alone (15/29, 51.7 %) or surgery with adjuvant radiotherapy (10/29, 34.4 %). 55.0 % (11/20) had positive margins on final pathology. Follow-up length varied (Range 75–146 months) and the overall survival was 85.0 %, with two unrelated deaths and one death likely attributed to OPMEC. Only one publication including 26 cases of OPMEC reported cancer specific survival outcomes, with 75 % 5-year and 65 % 10-year overall survival, and 86 % 5-year and 86 % 10-year distant metastases-free-survival.</div></div><div><h3>Conclusions</h3><div>OPMEC most often presents in females in their 50's as a base of tongue mass and has a high potential for nodal metastasis despite low or intermediate grading. Oncologic outcomes appear to be favorable following surgery with or without adjuvant therapy. Further research is needed to develop an evidence-based treatment strategy for patients with OPMEC.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100695"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraoperative optical biopsy assessment during TORS head and neck cancer resections-a novel application of confocal laser endomicroscopy with intravenous fluorescein","authors":"Harishanker Jeyarajan ,&nbsp;Isha Chaudhary ,&nbsp;Andrew Fuson ,&nbsp;Sherin James ,&nbsp;Akhilesh Wodeyar ,&nbsp;Matti Sievert ,&nbsp;Miguel Goncalves ,&nbsp;Carissa M. Thomas ,&nbsp;Jason Warram ,&nbsp;Bharat Akhanda Panuganti","doi":"10.1016/j.oor.2024.100702","DOIUrl":"10.1016/j.oor.2024.100702","url":null,"abstract":"<div><div>Margin assessment during transoral robotic surgical (TORS) resections of head and neck mucosal malignancies can be complex, originating in part from discrepancies in definitions of positive or close margins, and the technical difficulty of revising microscopic margins intraoperatively without incurring the functional consequences associated with soft tissue deficits in the oropharynx and larynx. Intraoperative optical imaging modalities, including confocal laser endomicroscopy (CLE), may represent an alternative or adjunctive option to delineate tumor footprint and assess for peripheral margin status. We present a case series describing our use of the Cellvizio® probe-based CLE platform as an intraoperative modality to assess for peripheral mucosal margins in the larynx, oropharynx, and hypopharynx during TORS resections using robotic instrumentation to establish basic feasibility and create the groundwork for future investigations of relative efficacy and impact on local recurrence rates.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100702"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular mechanisms and diagnostic innovations in HPV-associated head and neck squamous cell carcinomas: Insights into integration, epigenetic modifications, and biomarker applications","authors":"Geetha Shanmugam ,&nbsp;Gnanaprakash Jeyaraj ,&nbsp;Koustav Sarkar","doi":"10.1016/j.oor.2024.100710","DOIUrl":"10.1016/j.oor.2024.100710","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100710"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct extension from primary tumour to nodes: Can molecular profiling solve the dilemma?","authors":"Gargi Sarode,&nbsp;Dheeraj Meena,&nbsp;Sayali Tungikar,&nbsp;Atharv Shrotri,&nbsp;Sachin Sarode","doi":"10.1016/j.oor.2024.100664","DOIUrl":"10.1016/j.oor.2024.100664","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100664"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142420442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral oncology quality risk management: Tools and strategies to reduce risk","authors":"Shweta S. Yamgar ,&nbsp;Saee H. Thakur","doi":"10.1016/j.oor.2024.100671","DOIUrl":"10.1016/j.oor.2024.100671","url":null,"abstract":"<div><div>Oral oncology, which addresses the diagnosis and treatment of cancers in the oral cavity, presents unique challenges that demand an effective quality risk management (QRM) framework. This review explores the essential principles of QRM as they relate to oral oncology, focusing on the importance of patient safety and treatment effectiveness amidst complex care processes. The article outlines various tools and methodologies utilized for risk identification and mitigation, including Failure Mode and Effects Analysis (FMEA) and Root Cause Analysis (RCA), while emphasizing the need for standardized protocols to enhance consistency in treatment delivery. Furthermore, it evaluates innovative strategies aimed at increasing patient engagement and improving communication among healthcare providers, which are crucial for successful treatment outcomes. The integration of multidisciplinary teams and advanced technologies is highlighted as a pivotal aspect of QRM in oral oncology. By fostering a culture of continuous improvement and proactive risk management, healthcare stakeholders can better navigate the complexities of oral cancer treatment, ultimately leading to enhanced patient outcomes and safety. This comprehensive examination underscores the vital role of QRM in advancing the quality of care in oral oncology. Oral oncology focuses on diagnosing and treating cancers affecting the oral cavity, including the lips, gums, tongue, and salivary glands. With the rising global incidence of oral cancers, largely attributed to lifestyle factors such as tobacco and alcohol use, the urgency for effective diagnosis and treatment has never been greater. An effective quality risk management (QRM) framework is essential to enhance patient outcomes and safety.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100671"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142528984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crosstalk between cancer-associated fibroblasts (CAF) and tumour cells in head and neck cancer - Unraveling the complex pathway and CAF-targeted therapy","authors":"Nandhini J.,&nbsp;Karthikeyan E.","doi":"10.1016/j.oor.2024.100690","DOIUrl":"10.1016/j.oor.2024.100690","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100690"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143154343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Confronting the demonization of AI writing: Reevaluating its role in upholding scientific integrity","authors":"Luca Fiorillo","doi":"10.1016/j.oor.2024.100685","DOIUrl":"10.1016/j.oor.2024.100685","url":null,"abstract":"<div><div>The advent of AI-assisted writing tools, such as ChatGPT, has generated significant debate within scientific communities, primarily regarding their influence on the rigor and integrity of academic writing. While critics argue that reliance on these tools could dilute analytical depth or introduce biases, a balanced perspective suggests that AI-driven writing can enhance clarity, structure complex arguments, and improve the efficiency of scientific communication. This manuscript addresses the controversies surrounding AI writing by analyzing historical precedents of methodological errors in published research, highlighting the need for error-minimizing tools during manuscript preparation. Case studies of notable retractions and methodological critiques reveal that inaccuracies in scientific literature are not unique to the era of AI. These issues underscore the need for stringent ethical practices and critical evaluation, regardless of technological advancements. AI writing tools, when employed responsibly, serve as valuable assets to researchers by supporting precision and transparency in scholarly communication. Thus, embracing AI tools, rather than demonizing them, may contribute positively to the goals of reproducibility and trustworthiness in academic publications. Ethical guidelines and a commitment to integrity remain paramount as these tools evolve.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100685"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head and neck cancer treatment delays in 2021: Estimating distributional effects by site, surgery, and p16-positivity","authors":"Jason Semprini ,&nbsp;Kiran Marla","doi":"10.1016/j.oor.2024.100682","DOIUrl":"10.1016/j.oor.2024.100682","url":null,"abstract":"<div><h3>Background</h3><div>Following decades of policies increasing access to high-quality cancer treatment, the COVID-19 pandemic upended the U.S. healthcare system. The pandemic's disruption likely affected an often-overlooked dimension of quality cancer treatment: timely initiation. Timely treatment initiation is especially critical for head and neck cancer (HNC). We aimed to assess how the treatment interval (diagnosis to treatment initiation) changed in 2021 for different types of HNCs and treatment modalities.</div></div><div><h3>Methodology</h3><div>We analyzed Surveillance, Epidemiological, End Results (SEER) case data for years 2007–2021. Using ICD site codes, cancers were restricted to oropharynx, oral cavity, other pharynx, larynx. Oropharynx cancers were stratified by Human Papillomavirus (HPV) subtype based on p16-positivity codes. The outcome of interest was a variable measuring the number of days from diagnosis to treatment initiation. Cases were stratified by site and whether they received surgery as first course of treatment. To overcome validity threats from skewed treatment interval data and unobserved heterogeneity, we constructed an unconditional quantile regression model to estimate the effect of treatment in 2021 across the distribution of the treatment interval.</div></div><div><h3>Results</h3><div>155,273 patients in SEER initiated HNC treatment between 2007 and 2021. The median treatment interval was 29 days (Interquartile Range = 2–48). Among patients not receiving surgery, 2021 was associated with delayed treatment for all sites except oral cavity. For patients receiving surgery, 2021 was only associated with delayed treatment for p16+ Oropharynx cancer.</div></div><div><h3>Discussion</h3><div>HNC patients overall, but HPV+ Oropharynx cancer patients especially, experienced treatment delays in 2021. These delays, and their consequences, warrant policymaking attention.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"12 ","pages":"Article 100682"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142653553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}